{"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"groups":[{"description":"All participants received one cycle of lenalidomide (R), bortezomib (V) and dexamethasone (D) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD Alone participants received five additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study. After finishing protocol-specified treatment, off-study salvage transplantation was recommended but not mandated for RVD Alone participants at relapse.\n\nRVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12","id":"BG000","title":"RVD Alone"},{"description":"All participants received one cycle of lenalidomide (R), bortezomib (V) and dexamethasone (d) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD plus autologous stem cell transplant (ASCT) participants received high-dose melphalan (200 mg/m2, adjusted for ideal body weight) ASCT and, upon recovery (\\~day 60), two additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study.\n\nAfter finishing protocol-specified treatment, RVD plus ASCT participants could undergo a second transplant.\n\nRVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12","id":"BG001","title":"RVD Plus ASCT"},{"description":"Some participants started cycle 1 lenalidomide (R), bortezomib (V) and dexamethasone (D) therapy but were not randomized.\n\nRVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12","id":"BG002","title":"RVD Cycle 1 Only"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"25","upperLimit":"66","value":"57"},{"groupId":"BG001","lowerLimit":"30","upperLimit":"65","value":"55"},{"groupId":"BG002","lowerLimit":"55","upperLimit":"65","value":"59"},{"groupId":"BG003","lowerLimit":"50","upperLimit":"61","value":"56"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"308"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"202"},{"groupId":"BG001","value":"215"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"421"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"42"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"336"},{"groupId":"BG001","value":"332"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"675"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"12"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"272"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"545"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"134"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"20"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"18"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"12"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"184"},{"groupId":"BG003","value":"362"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"722"}],"units":"Participants"}],"title":"I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"134"},{"groupId":"BG003","value":"264"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"722"}],"units":"Participants"}],"title":"II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"47"},{"groupId":"BG003","value":"96"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"722"}],"units":"Participants"}],"title":"III"}],"description":"The International Staging System (ISS) consists of three stages: stage I, serum beta 2-microglobulin level lower than 3.5 mg per liter and serum albumin level 3.5 g per deciliter or higher; stage II, neither stage I nor III; and stage III, serum beta 2-microglobulin level 5.5 mg per liter or higher. Higher stages indicate more severe disease.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ISS Multiple Myeloma staging data collected at randomization and therefore data was not collected for the seven participants who were not randomized.","title":"ISS Multiple Myeloma Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"66"},{"groupId":"BG003","value":"132"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"722"}],"units":"Participants"}],"title":"High risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"274"},{"groupId":"BG003","value":"542"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"722"}],"units":"Participants"}],"title":"Standard risk"}],"description":"Cytogenetic risk was based on FISH or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (t\\[4;14\\], t\\[14;16\\], or del17p). Patients with standard risk had no high-risk cytogenetic abnormalities.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cytogenetic risk category data collected at randomization and therefore data was not collected for the seven participants who were not randomized.","title":"Cytogenetic Risk Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"162"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"<25"},{"categories":[{"measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"270"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"25 to <30"},{"categories":[{"measurements":[{"groupId":"BG000","value":"136"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"297"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":">/= 30"}],"description":"The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.","paramType":"COUNT_OF_PARTICIPANTS","title":"BMI","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"153"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"321"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"341"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"66"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"357"},{"groupId":"BG001","value":"365"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"729"}],"units":"Participants"}],"title":"Unknown"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status: (PS0) Fully active, able to carry on all pre-disease performance without restriction (PS1) Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (PS2) Ambulatory and capable of all self-care but unable to carry out any work activities; Up and about \\>50% of waking hours.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"All enrolled participants."}